Al-Marsad Newspaper: Experts revealed the emergence of a new “killer” immunotherapy, which is a promising hope for attacking difficult-to-treat cancers.
The new drug, known as AFM24, was trialled by the Institute of Cancer Research (ICR) in London and the Royal Marsden NHS Foundation. It showed signs of efficacy in a third of patients with a range of advanced cancers that had stopped responding to treatment, including bowel, lung and pancreatic cancers.
AFM24, which is administered intravenously, was generally well tolerated by patients.
The Institute of Cancer Research said the immunotherapy has a “warhead” that targets EGFR, which is normally produced by cancers of the lung, intestine, kidney, stomach, pancreas and bile ducts.
Dr Juanita Lopez, the UK trial leader, from the Institute of Cancer Research and Medical Oncology at Royal Marsden, said: ‘This new immunotherapy AFM24 can redirect natural killer cells to tumors by targeting a protein called EGFR, which is often found on the surface of cancer cells. “.
